Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — Shareholder Meeting (May 2023)
34 slides from Vita Life Sciences's shareholder meeting presentation, May 9, 2023
Slide 1: AGM Address & Presentation ASX cover letter
9 May 2023 Market Announcements Australian Securities Exchange Ltd 20 Bridge Street For personal use only Sydney, NSW 2000 Dear Sir/ Madam, ANNUAL GENERAL MEETING‐ADDRESS & PRESENTATION The Vita Life Sciences Ltd addresses to the 2023 AGM by the Chairman and the Managing Director with related presen
Slide 2: Chairman's Script - Welcome and Introduction
Vita Life Sciences Limited – 2023 Annual General Meeting Chairman’s Script - 9 May 2023 Welcome Good afternoon, ladies and gentlemen. I am Henry Townsing, the Chairman of Vita Life Sciences Limited and the Chairman for the Annual General Meeting today. Welcome to the VLS 2023 Annual General Meeting.
Slide 3: Chairman's Script - Meeting Procedure
As this meeting is being conducted as a hybrid meeting, I would like to welcome those shareholders that are joining us online and ask that you please submit any questions or comments via the Q&A function which can be found at the bottom of your screen. When you submit a question or comment, please s
Slide 4: Chairman's Script - Voting Instructions
Shareholders in attendance online who have already submitted their votes by proxy should note that your votes will already be counted towards the poll. You do not need to lodge another vote unless you wish to change your votes. Shareholders in attendance online who have not submitted their votes by
Slide 5: Chairman's Script - Financial Reports and Remuneration Report
The Company’s auditor for the 2022 financial year, Mr Joseph Santangelo of Nexia Sydney Audit Pty Ltd are present to take questions relevant to the conduct of the audit and the preparation and content of the independent auditor’s report. If you have any questions or wish to discuss this resolution,
Slide 6: Chairman's Script - Resolution 2
[PAUSE AND TAKE QUESTIONS] Members of the Company’s key management personnel who were named in the FY2022 remuneration report and their closely related parties are reminded that they may not vote on this resolution. Shareholders may now vote on Resolution 1. May I again remind shareholders not to cl
Slide 7: Chairman's Script - Share Buy-Back Resolution
Resolution 3: Re-election of Director- Mr Gregory Ralph In view of Mr Ralph dying after the notice of meeting was dispatched to shareholders resolution 3 is withdrawn. Resolution 4: Share-Buy Back I put forward Resolution 4: To consider and, if thought fit, to pass, with or without amendment, Resolu
Slide 8: Chairman's Script - Other Business, Resolution 5
AGENDA 3 OTHER BUSINESS Is there any other business that can lawfully be brought forward by a shareholder? Mr Khoo proposes new resolution 5 Henry: Mr Khoo’s proposed resolution arises from the death of Mr Ralph. Under the For personal use only Company’s Constitution a Shareholder may propose a reso
Slide 9: Chairman's Script - Voting and Close
Henry: Thank you Andrew. For those Shareholders voting on-line you please cast your votes on Resolutions 1, 2, 4 and 5. The number of valid proxy votes that have been received for resolutions before today’s meeting are shown on the screen. If you have any questions in relation to the submission of o
Slide 10: Address by the Managing Director - Opening remarks
Vita Life Sciences Limited – 2023 Annual General Meeting Address by the Managing Director – 9 May 2023 Opening remarks Thank you, Henry. Just before I begin, I would like to take a moment to recognise the invaluable contributions made by the late Mr Gregory Ralph. Mr Ralph was a Non‐Executive Direct
Slide 11: Managing Director's Address - New Markets
In some exciting news, the company launched Herbs of Gold into the New Zealand market through the Green Cross Pharmacy chain. The New Zealand market now provides a great platform to round out our market penetration across the region. In addition, Vietnam has been identified as an emerging market for
Slide 12: Strategic Priorities
Strategic Priorities The Company continues to demonstrate its prudent financial disciplines. Our business has emerged from 2022 in even better shape, maintaining its strong balance sheet and strong cash position. The Company will continue to invest across key strategic pillars and leverage market po
Slide 13: Annual General Meeting
For personal use only Annual General Meeting 9 May 2023
Slide 14: AGM Agenda
AGM Agenda For personal use only 1. CHAIRMAN’S WELCOME ADDRESS 2. MANAGING DIRECTOR’S REVIEW 3. ORDINARY RESOLUTIONS 4. QUESTIONS & ANSWERS ANNUAL GENERAL MEETING 2023
Slide 15: Henry Townsing, Chairman
For personal use only Henry Townsing Chairman Mr Townsing brings over 30 years’ experience in corporate finance and private equity. He was a Director of the Company, from 1985 to 1992, 2004 to 2009 and was reappointed a Director on 22nd December 2011. Mr Townsing was appointed as the Chairman of the
Slide 16: AGM Agenda
AGM Agenda For personal use only 1. CHAIRMAN’S WELCOME ADDRESS 2. MANAGING DIRECTOR’S REVIEW 3. ORDINARY RESOLUTIONS 4. QUESTIONS & ANSWERS ANNUAL GENERAL MEETING 2023
Slide 17: Andrew O'Keefe, Managing Director
For personal use only Andrew O’Keefe Managing Director Mr O’Keefe was appointed Managing Director on 1st January 2017. Mr O’Keefe has over 20 years’ experience within the Australian pharmaceutical and healthcare industry. During his career Mr O’Keefe has held senior leadership positions in publicly
Slide 18: Synopsis of Business Operations
Synopsis of Business For personal use only Operations Distribution - Across several markets; Australia, Malaysia, Singapore, China, Vietnam, Thailand and Indonesia Brands – Herbs of Gold, VitaHealth & VitaScience brands Products – 750 registered products across all markets Strong consumer demand – T
Slide 19: Awards & Recognition
Awards & Recognition • Advantage Pharmacy Survey - Ranked Herbs of Gold 2nd in the Advantage Annual Pharmacy Voice of Customer Program 2022 (Over the Counter For personal use only Benchmark Set) • Herbs of Gold awarded Supply Chain of the Year with National Pharmacies Group • Herbs of Gold awarded G
Slide 20: Marketing Overview
Marketing Overview For personal use only ANNUAL GENERAL MEETING 2023
Slide 21: Financial Performance
Financial Performance For personal use only Record Sales Pre-Tax Profit Balance sheet equity Dividend payment $66.9m, up 17% $10.7m, down 4% $36.5m, net cash $15.7m 6.00 cents/share, (without any borrowings) up 4% ANNUAL GENERAL MEETING 2023
Slide 22: Global Performance
Global Performance For personal use only Australia is the single largest market with an increase of 3% to 56% in market share. 2022 revenue by geography Other Asia 3% $2.3M Australia 56% Singapore 9% $5.8M $37.3M Asia Total 44% revenue $66.9m Malaysia 32% $21.4M ANNUAL GENERAL MEETING 2023
Slide 23: Strategic Priorities
Strategic priorities For personal use only Our pillars BRAND BUILDING EDUCATION & INNOVATION TALENT WELLBEING OPERATIONAL LEVERAGE Key initiatives to support our pillars OVER 1400 RECRUITMENT OF NATIONAL NEW BUSINESS MODEL IN NEW ERP SYSTEM INCREASED BRANDING & PHARMACIES RANGING TRAINING TEAM 30 NE
Slide 24: For personal use only
For personal use only ANNUAL GENERAL MEETING 2023
Slide 25: Outlook
Outlook For personal use only • The Group continues to be very well positioned to leverage market opportunities across the region. • The plans and vision for the business are strong and robust to drive future growth. • First half guidance will be provided in June. ANNUAL GENERAL MEETING 2023
Slide 26: AGM Agenda
AGM Agenda For personal use only 1. CHAIRMAN’S WELCOME ADDRESS 2. MANAGING DIRECTOR’S REVIEW 3. ORDINARY RESOLUTIONS 4. QUESTIONS & ANSWERS ANNUAL GENERAL MEETING 2023
Slide 27: Ordinary Resolutions
Ordinary Resolutions For personal use only 1. Remuneration Report 2. Re-election of Director – Jack Teoh 3. Re-election of Director- Greg Ralph (Now Withdrawn) 4. Share buy back 5. Re-election of Director- Henry Townsing ANNUAL GENERAL MEETING 2023
Slide 28: Proxy-Resolution 1
Proxy-Resolution 1 For personal use only PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION 1) Adoption of the Remuneration Report 11,917,659 51,364 14,720,908 12,746,799 ANNUAL GENERAL MEETING 2023
Slide 29: Proxy-Resolution 2
Proxy-Resolution 2 For personal use only PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION Re-election of Director 2) 16,148,547 24,468 14,830,022 8,154,218 (Jack Teoh) ANNUAL GENERAL MEETING 2023
Slide 30: Proxy-Resolution 3
Proxy-Resolution 3 For personal use only PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION Re-election of Director 3) 14,736,944 3,468 22,483,329 - (Gregory Ralph) ANNUAL GENERAL MEETING 2023
Slide 31: Proxy-Resolution 4
Proxy-Resolution 4 For personal use only PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION 4) Share buy-back 24,431,097 2,500 15,002,383 - ANNUAL GENERAL MEETING 2023
Slide 32: Proxy
Proxy For personal use only PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION 1) Adoption of the Remuneration Report 11,817,659 51,364 14,720,908 12,746,799 Re-election of Director 2) 16,148,547 24,468 14,830,022 8,154,218 (Jack Teoh) Re-election of Director - 3) 14,736,944 3,468 22,483,329
Slide 33: AGM Agenda
AGM Agenda For personal use only 1. CHAIRMAN’S WELCOME ADDRESS 2. MANAGING DIRECTOR’S REVIEW 3. ORDINARY RESOLUTIONS 4. QUESTIONS & ANSWERS ANNUAL GENERAL MEETING 2023
Slide 34: Disclaimer
For personal use only Disclaimer This document has been prepared by Vita Life Sciences Limited (Vita Life Sciences) and comprises written material/slides for a presentation concerning Vita Life Sciences. The presentation is for information purposes only and does not constitute or form part of any of